



August 1, 2017

## Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017

EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas' management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

### Investor Conference Call and Webcast

The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers. The webcast can be accessed live via the investor section of the Adamas website at <http://ir.adamaspharma.com/events.cfm> and will be available for replay until September 8, 2017.

### About Adamas Pharmaceuticals, Inc.

At Adamas, we believe in the power and the promise of medicines derived from a deep understanding of time-dependent biology. Our expertise lies in uncovering and mapping the relationship between disease and drug activity timing patterns. From there, we strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect. This unique understanding of time-dependent biological processes informs our every innovation, targeting advancement in treatment of chronic neurologic disorders. Our proprietary portfolio includes ADS-5102, a high-dose amantadine therapy taken once-daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease, and ADS-4101, a high-dose lacosamide therapy taken once-daily at bedtime, in Phase 1 clinical development for the treatment of partial onset seizures in people with epilepsy. The New Drug Application for ADS-5102 is under review by the U.S. Food and Drug Administration with a PDUFA date of August 24, 2017.

Additionally, Adamas' licensed assets are currently marketed by Allergan under the brand names NAMENDA XR<sup>®</sup> and NAMZARIC<sup>®</sup>, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit [www.adamaspharma.com](http://www.adamaspharma.com).

NAMENDA XR<sup>®</sup> and NAMZARIC<sup>®</sup> are trademarks of Merz Pharma GmbH & Co. KGaA.

Contact:

Ashleigh Barreto

Director, Corporate Communications & Investor Relations

Adamas Pharmaceuticals, Inc.

Phone: 510-450-3567

Email: [ir@adamaspharma.com](mailto:ir@adamaspharma.com)

 Primary Logo

Source: Adamas Pharmaceuticals, Inc.

News Provided by Acquire Media